Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Aileron Therapeutics reports Q3 EPS (13c), consensus (15c) » 19:05
11/12/20
11/12
19:05
11/12/20
19:05
ALRN

Aileron Therapeutics

$1.06 /

-0.05 (-4.50%)

"We recently…

"We recently achieved the critical milestone of clinical proof of concept of ALRN-6924, demonstrating a protective effect against severe anemia, thrombocytopenia and neutropenia in our ongoing Phase 1b trial of patients with p53-mutated small cell lung cancer undergoing treatment with topotecan," said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer of Aileron. "These positive findings help inform our future clinical development strategy, which involves advancing randomized, controlled studies of ALRN-6924 in large cancer indications, including, non-small cell lung cancer, gastrointestinal cancers such as colorectal cancer, and other cancers."

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.06 /

-0.05 (-4.50%)

ALRN Aileron Therapeutics
$1.06 /

-0.05 (-4.50%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.06 /

-0.05 (-4.50%)

  • 04
    Jun
Over a month ago
Conference/Events
Aileron Therapeutics to host conference call » 08:25
10/26/20
10/26
08:25
10/26/20
08:25
ALRN

Aileron Therapeutics

$1.92 /

-0.19 (-9.00%)

Management will discuss…

Management will discuss the Company's presentation at the 32nd EORTC-NCI-AACR Virtual Symposium on a conference call to be held on October 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

  • 04
    Jun
Conference/Events
Aileron Therapeutics to host conference call » 04:55
10/26/20
10/26
04:55
10/26/20
04:55
ALRN

Aileron Therapeutics

$1.92 /

-0.19 (-9.00%)

Management will discuss…

Management will discuss the Company's presentation at the 32nd EORTC-NCI-AACR Virtual Symposium on a conference call to be held on October 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

  • 04
    Jun
Hot Stocks
Aileron announces proof-of-concept data from ALRN-6924 Phase 1b trial » 15:31
10/25/20
10/25
15:31
10/25/20
15:31
ALRN

Aileron Therapeutics

$1.92 /

-0.19 (-9.00%)

Aileron Therapeutics…

Aileron Therapeutics announced new positive clinical data from its ongoing Phase 1b trial demonstrating clinical proof of concept that treatment with ALRN-6924 prior to second-line topotecan administration resulted in a protective effect against severe anemia, thrombocytopenia and neutropenia in patients with p53-mutated small cell lung cancer. The results are being featured in a late-breaking poster presentation at the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics. ALRN-6924 is a cell-permeating peptide drug designed to work intracellularly, activating wild-type p53 to selectively shield healthy cells from chemotherapy in patients who harbor p53-mutant tumors, approximately 50% of all cancer patients, without interrupting chemotherapy's targeting of cancer cells. As of August 31, 2020, the data cut-off for this data presentation, a total of 26 adult patients were enrolled in the dose optimization part of the ALRN-6924 Phase 1b trial, evaluating treatment with ALRN-6924 given 24 hours prior to chemotherapy. 18 patients were enrolled across three ALRN-6924 dose levels and an additional eight patients were enrolled in a 0.3 mg/kg expansion cohort. 25 of these patients were evaluable per the trial protocol. ALRN-6924 was administered 24 hours before each dose of topotecan. Topotecan was administered on days 1 through 5 of every 21-day treatment cycle. In the trial, toxicities were evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Per the Phase 1b trial protocol, patients were not permitted to receive prophylactic G-CSF treatment in cycle 1. Across all ALRN-6924 dose levels, Grade 3/4 anemia, Grade 3/4 thrombocytopenia and Grade 4 neutropenia were limited to 24%, 36% and 48% of patients, respectively. In the topotecan plus placebo arm of a recent third-party randomized Phase 2 trial in SCLC patients receiving topotecan, Grade 3/4 anemia, Grade 3/4 thrombocytopenia and Grade 4 neutropenia were reported in 63%, 70% and 76% of patients, respectively. In the ALRN-6924 trial, while chemoprotection effects were observed across all ALRN-6924 dose levels, the 0.3 mg/kg dose level showed the most robust chemoprotection results, with Grade 3/4 anemia, Grade 3/4 thrombocytopenia and Grade 4 neutropenia limited to 21%, 36% and 43% of patients, respectively. Additionally, none of the patients on ALRN-6924 experienced febrile neutropenia. In the topotecan plus placebo arm of the recent third-party randomized Phase 2 trial in SCLC patients receiving topotecan, febrile neutropenia was observed in 17% of patients. None of the patients treated at the 0.3 mg/kg ALRN-6924 dose level had hematological serious adverse events and only one patient received one red blood cell transfusion and one platelet transfusion1. In the topotecan plus placebo arm of the recent third-party randomized Phase 2 trial, 41% and 31% of SCLC patients received red blood cell and platelet transfusions, respectively. At the 0.3 mg/kg ALRN-6924 dose level, no patients required erythropoiesis-stimulating agents, and seven patients required G-CSF treatment.

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

  • 04
    Jun
Conference/Events
Aileron Therapeutics to host conference call » 11:33
10/25/20
10/25
11:33
10/25/20
11:33
ALRN

Aileron Therapeutics

$1.92 /

-0.19 (-9.00%)

Management will discuss…

Management will discuss the Company's presentation at the 32nd EORTC-NCI-AACR Virtual Symposium on a conference call to be held on October 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

  • 04
    Jun
Hot Stocks
Aileron Therapeutics to present PoC data for ALRN-6924 at ENA 2020 » 07:02
10/12/20
10/12
07:02
10/12/20
07:02
ALRN

Aileron Therapeutics

$1.55 /

-0.07 (-4.32%)

Aileron Therapeutics…

Aileron Therapeutics announced that proof-of-concept data from the company's Phase 1b study of ALRN-6924 will be featured in a late-breaking poster presentation during the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 - 25, 2020. The abstract entitled, "Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDM2/MDMX inhibitor ALRN-6924," will be presented starting Saturday, October 24, on the ENA 2020 website. The data to be presented is from Aileron's Phase 1b study, which is evaluating ALRN-6924 as a therapeutic agent administered ahead of chemotherapy to prevent chemotherapy-induced toxicities, such as severe anemia, neutropenia and thrombocytopenia, in patients with p53-mutated small cell lung cancer who are being treated with the chemotherapy topotecan. In June 2020, Aileron announced positive interim data from this study. Aileron's long-term vision is to bring chemoprotection to all patients with p53-mutated cancers, which represent at least 50% of cancer patients, regardless of cancer type or chemotherapy.

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.55 /

-0.07 (-4.32%)

ALRN Aileron Therapeutics
$1.55 /

-0.07 (-4.32%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.55 /

-0.07 (-4.32%)

  • 04
    Jun
Syndicate
Aileron Therapeutics files to sell 10.55M shares of common stock for holders  16:58
10/05/20
10/05
16:58
10/05/20
16:58
ALRN

Aileron Therapeutics

$1.24 /

+0.07 (+5.98%)

 
ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.24 /

+0.07 (+5.98%)

ALRN Aileron Therapeutics
$1.24 /

+0.07 (+5.98%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.24 /

+0.07 (+5.98%)

  • 04
    Jun
Hot Stocks
Aileron Therapeutics enters $15M common stock purchase with Lincoln Park Capital » 18:09
09/21/20
09/21
18:09
09/21/20
18:09
ALRN

Aileron Therapeutics

$1.28 /

-0.12 (-8.57%)

Aileron Therapeutics…

Aileron Therapeutics announced it has entered into a common stock purchase agreement for up to $15M with Lincoln Park Capital Fund. In connection with the execution of the purchase agreement, LPC made an initial purchase of $500,000 of common stock at $1.36 per share. Thereafter, Aileron will have the option, but not the obligation, to sell to LPC up to an additional $14.5 million in shares of common stock over a thirty-six-month period subject to certain conditions, including a registration statement being filed and declared effective by the SEC.

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.28 /

-0.12 (-8.57%)

ALRN Aileron Therapeutics
$1.28 /

-0.12 (-8.57%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.28 /

-0.12 (-8.57%)

  • 04
    Jun
Over a quarter ago
Syndicate
Aileron Therapeutics files to sell 3.7M shares of common stock for holders  16:34
08/11/20
08/11
16:34
08/11/20
16:34
ALRN

Aileron Therapeutics

$1.27 /

+0.02 (+1.60%)

 
ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.27 /

+0.02 (+1.60%)

ALRN Aileron Therapeutics
$1.27 /

+0.02 (+1.60%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.27 /

+0.02 (+1.60%)

  • 04
    Jun
Earnings
Aileron Therapeutics reports Q2 EPS (14c), consensus (19c) » 17:34
08/05/20
08/05
17:34
08/05/20
17:34
ALRN

Aileron Therapeutics

$1.48 /

+0.38 (+34.55%)

We continue to make…

We continue to make important progress advancing our goal to deliver a novel chemoprotective medicine that can protect cancer patients against multiple serious, often life-threatening chemotherapy-induced side effects," said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer of Aileron. "We're pleased with the preliminary data we reported in June from the dose optimization part of our ongoing Phase 1b proof-of-concept clinical trial of ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in small cell lung cancer patients undergoing treatment with topotecan. These data showed clinically meaningful protection against severe chemotherapy-induced anemia and thrombocytopenia. In addition, a signal of protection against Grade 4 neutropenia in the first treatment cycle was observed at the 0.3 mg/kg dose level." Dr. Aivado further commented, "Key inflection points for Aileron in the coming months include final Phase 1b dose optimization data in addition to preliminary data from the recently initiated schedule optimization part of the trial, both in the fourth quarter, as well as the initiation of our healthy volunteer study of ALRN-6924 in the third quarter. These milestones will further support and de-risk our plans to expand development of ALRN-6924 for multiple cancer types and various chemotherapies, to ultimately deliver this unique chemoprotective medicine to as many patients with p53-mutated cancers as possible, which could translate to approximately half of all cancer patients." Cash Position: Cash, cash equivalents and investments as of June 30, 2020 were $18.9 million, compared to $18.3 million as of December 31, 2019.

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.48 /

+0.38 (+34.55%)

ALRN Aileron Therapeutics
$1.48 /

+0.38 (+34.55%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.48 /

+0.38 (+34.55%)

  • 04
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.